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HPV status, p16 expression, clinicopathological factors, and 
survival were analyzed. TLR 5, 7, and 9 expression pat-
terns differed between HPV-positive and -negative tumors, 
and they were statistically significantly associated with his-
tory of smoking, heavy drinking, tumor site, grade, size 
(T), metastasis (N), and stage. Moreover, in HPV-positive 
tumors the expression of TLR 5 and 7 correlated with tumor 
recurrence. After adjustment, among HPV-positive OPSCC 
patients, high TLR 5 and low TLR 7 expression were associ-
ated with poor disease-specific survival. Our results indicate 
that TLR 5 and 7 may have a role in the prognostication of 
HPV-positive OPSCC, however, further studies are needed 
to clarify the comprehensive role of these TLRs in OPSCC.
Keywords Head and neck cancer · Oropharynx · 
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Abbreviations
CI  Confidence interval
CRT  Chemoradiotherapy
DSS  Disease-specific survival
HR  Hazard ratio
ISH  In situ hybridization
OPSCC  Oropharyngeal squamous cell carcinoma
RFS  Recurrence-free survival
RT  Radiotherapy
SCC  Squamous cell carcinoma
Sx  Surgery
Introduction
Predicting survival of oropharyngeal squamous cell carci-
noma (OPSCC) has changed fundamentally over the last 
Abstract A large subset of oropharyngeal squamous 
cell carcinomas (OPSCCs) is associated with HPV infec-
tion and has better outcome than non-viral-related tumors. 
Various malignancies also carry a role for TLRs, key acti-
vators of inflammation and innate immunity. We examined 
the expression of TLRs in OPSCC, and their association 
with HPV status and treatment outcome. TLR 5, 7, 9, and 
p16 were studied by immunohistochemistry and HPV status 
was detected with in situ hybridization in 202 tumors of 
consecutively treated OPSCC patients using tissue micro-
array method. The relations between TLR expression and 
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two decades, since HPV was discovered to divide these 
tumors into two biologically distinct subgroups [1]. Whilst 
the incidence of HPV-associated OPSCC has increased in 
many Western Countries [2–5], its favorable survival has 
become widely recognized [6]. In addition to HPV status, 
treatment response and outcome are influenced by history 
of smoking, and tumor and nodal status. Patients can be 
divided into three distinct risk-of-death categories accord-
ing to these factors [7]. The biology explicating these dif-
ferences in tumor behavior remains largely unknown, but 
it is obvious that a clear understanding of it could aid the 
selection for treatment paradigm and improve outcome [8]. 
The treatment guidelines for HPV-positive OPSCC warrant 
new evaluation due to its generally good outcome, which 
indicates that a subset of these patients might benefit from 
treatment de-escalation [9].
TLRs 1–10 recognize molecular patterns, which initi-
ate immunological defense against pathogens, such as bac-
teria and viruses [10, 11]. TLR activation can also occur 
due to endogenous release of damage- or danger-associated 
structures, whereupon affected or dying cells can activate 
immunological defenses [12, 13]. TLR signaling has been 
suggested to have carcinogenic effects, but TLR signaling 
may also induce anti-tumor responses and prevent tumor 
progression [14, 15]. In OPSCC, the expression of TLR 5, 
7, and 9 varies according to the tumor HPV status [16]. In 
addition, these TLRs have been found to be prognostic in 
various cancers although their prognostic role in OPSCC 
remains unknown [17–27].
The objective of this study on a series of 202 unselected 
consecutive patients was to determine if the expression of 




The patient cohort covering a 10-year period from 2000 to 
2009 comprised 331 consecutive patients with oropharyn-
geal cancer diagnosed at the Helsinki University Hospi-
tal. Patient inclusion based on the following International 
Classification of Diseases 10th revision codes: C01, C02.4, 
C05.1, C05.2, C05.8, C05.9, C09.0, C09.1, C09.8, C09.9, 
C10.0, C10.2, C10.3, C10.8, and C10.9. We excluded from 
the analyses the patients with palliative treatment (n = 44), 
concurrent head and neck squamous cell carcinoma (n = 5), 
earlier treatment for head and neck squamous cell carcinoma 
(n = 11), other histology than squamous cell carcinoma 
(SCC) or subtype of SCC (n = 18), or tumor tissue unavail-
ability (n = 51).
We collected clinicopathologic data from hospital reg-
istries and recorded details on patients age, sex, tumor his-
tology, grade, TNM class, stage, primary treatment [i.e., 
surgery (Sx), radiotherapy (RT) and chemoradiotherapy 
(CRT)], tumor recurrence, treatment of recurrent disease, 
and status at last follow-up. Statistics Finland provided the 
dates and causes of death. All patients had a minimum fol-
low-up of 3 years or until death. The Research Ethics Board 
at the Hospital District of Helsinki and Uusimaa approved 
the study design and a research permission was granted.
Of all 202 patients, 130 underwent primary Sx, and 116 
received adjuvant oncological treatment (RT or CRT). No 
postoperative oncological therapy was provided for 14 
patients because of Stage I–II disease (five cases), or patient-
related factors (nine cases). Altogether 72 patients received 
definitive CRT or RT, of which 11 underwent salvage Sx 
in the primary treatment phase (primary site only n = 1, 
neck only n = 7, primary site and neck n = 3). Tissue sam-
ples were collected before RT or CRT for all but two cases, 
where only the post treatment specimens were available for 
immunohistochemistry.
Immunohistochemistry
Tissue microarray blocks were prepared and immunohisto-
chemical staining was performed as described earlier [28]. 
Our primary antibodies were: Monoclonal mouse anti-
human TLR 5 (1:200, IMG-664A Imgenex), monoclonal 
rabbit anti-human TLR 7 (1:300, IMG-581A Imgenex), 
polyclonal rabbit anti-human TLR 9 (1:100, sc-25468 Santa 
Cruz Biotechnology), and monoclonal mouse anti-human 
 p16INK4a (9517 CINtec Histology Kit, MTM laboratories).
Immunoscore
Two researchers (J. H. and H. M.) separately scored the tis-
sue microarray slides that were temporarily decoded to avoid 
their identification. In case of discordance, consensus was 
achieved. The positivity of TLRs 5, 7, and 9, was scored as 
previously described [16]. TLRs 5, 7, and 9 were scored 
based on the intensity of staining, because if present, most 
of the tumor cells stained positive. The intensity of TLRs 5 
and 9 was scored as follows: none (0), mild (1), moderate 
(2), and strong (3). TLR 7 mainly localized to the mem-
brane and it was scored as follows: none (0) if no TLR 7 
was observed, mild (1) if some nuclear membranes were 
positive, moderate (2) if all nuclear membranes and some 
nuclei were stained, and strong (3) if nuclear membranes and 
nuclei stained substantially. The tumor was regarded as p16 
positive if over 70% of cells were strongly immunopositive. 
Whenever several tumor spots were available for analysis, 
the average TLR immunoscore was used, whereas p16 was 
stated as positive if any tumor spot was positive.
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HPV in situ hybridization
The Ventana Inform HPV in situ hybridization (ISH) assay 
was performed with a high-risk HPV probe and iVIEW 
Blue detection kit in Benchmark XT series stainer (Tuscon, 
Arizona, USA). The assay was performed from 5-μm thick 
sections, using extended Ventana cell-conditioning solution 
(CC2) pretreatment with an incubation time of 32 min with 
ISH protease 3. Affinity to following high-risk HPV sub-
types has been demonstrated: 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, and 66. HPV status was regarded as positive if 
any spot was positive using ISH.
Statistical analysis
We used SPSS Version 20.0 (SPSS, Inc., Chicago, IL, 
USA) for statistical analyses. Chi-square test with asymp-
totic and exact P values was used when best appropriate 
to calculate the statistical differences between categorical 
variables. TLR 7 scorings for “none” and “mild” were pro-
cessed together, given the low number of TLR 7-negative 
tumors. The 5-year disease-specific survival (DSS) rates and 
recurrence-free survival (RFS) rates were calculated using 
the Kaplan–Meier estimate. The statistical significance in 
Kaplan–Meier analysis was calculated with the log-rank test. 
The follow-up time in DSS analysis was defined as a time 
period between the last treatment day and end of follow-up 
or death with disease. The maximum length of follow-up 
was adjusted to 5 years to minimize follow-up bias. RFS 
time was calculated from the last treatment day to the detec-
tion of cancer recurrence either in the primary tumor site, in 
regional lymph nodes, or in both, or at distant sites. To pre-
sent the differences between locoregional and distant RFS, 
in RFS analysis we censored all patients who died either 
of persistent OPSCC in the primary treatment phase or of 
other causes. The Cox proportional hazards model was used 
for multivariate survival analysis. Clinically relevant vari-
ables with a univariate P value less than 0.1 were included in 
multivariate analysis. The proportional hazards assumptions 
were tested with log–log curves. A two-sided P value less 
than 0.05 was considered statistically significant.
Results
HPV and p16
Of the total 202 tumors, 105 (52%) were HPV positive and 
97 (48%) HPV negative. p16 staining revealed 117 (58%) 
p16-positive and 85 (42%) p16-negative tumors. The sen-
sitivity and specificity for p16 in determining HPV status 
were 96.2 and 83.5%, respectively. Table 1 shows baseline 
characteristics of patients and expression of TLR 5, 7, and 
9. The expression of TLR 5 in HPV-positive tumors was 
significantly lower than in HPV-negative tumors. TLR 7 
was, however, eminently more expressed in HPV-positive 
tumors. The expression of TLR 9 was significantly lower in 
HPV-positive tumors than in HPV-negative tumors. Results 
of HPV ISH and immunohistochemical staining with anti-
bodies for p16, and TLR 5, 7, and 9 are presented in Fig. 1.
TLR expression and its association with patient 
and tumor characteristics (Table 2)
TLR 5 expression was more prominent among smokers and 
heavy drinkers and less prominent in small (T1) tumors, 
in regionally advanced metastatic (N2–3) disease, in Stage 
III–IV diseases, in tumors arising from tonsil, and in Grade 
3 tumors. TLR 7 expression was low in patients with his-
tory of smoking and heavy drinking. TLR 7 expression was, 
however, higher in regionally advanced metastatic (N2–3) 
disease and in Stage III–IV disease, in tumors arising from 
lateral wall and in anterior wall and in Grade 3 tumors. High 
TLR 9 expression was associated with current smoking, but 
not with any other investigated factors.
TLR expression and associations with tumor 
recurrence and outcome (Fig. 2; Table 3)
Low TLR 5 expression was associated with favorable 5-year 
locoregional RFS, but it lacked a statistically significant cor-
relation with 5-year distant RFS. Patients with low TLR 5 
expression had better DSS. The 5-year DSS rates according 
to TLR 5 staining categories were as follows: 0 = 88.1%, 
1 = 77.1%, 2 = 70.8%, and 3 = 49.8%. TLR 7 expression 
had no statistically significant association with 5-year RFS. 
Patients with tumors expressing TLR 7 at high levels had 
better DSS. The 5-year DSS rates according to TLR 7 stain-
ing categories were as follows: 1 = 52.7%, 2 = 73.2%, and 
3 = 88.2%. The association between TLR 9 and 5-year RFS 
or DSS was absent.
TLR expression was associated with recurrence rate 
and DSS in patients with HPV‑positive tumors (Fig. 2; 
Table 3)
HPV-positive tumors typically had low TLR 5 and 9 expres-
sion and high TLR 7 expression with good outcome. How-
ever, in patients with a HPV-positive tumor, high expression 
of TLR 5 and low expression of TLR 7 were associated 
with poor 5-year locoregional RFS. Low TLR 7 expres-
sion was also associated with poor 5-year distant RFS. 
Among patients with HPV-positive disease, the expression 
of TLR 5 and 7, but not TLR 9, influenced DSS. Patients 
having low TLR 5 expression had better DSS. The 5-year 
DSS of patients according to TLR 5 staining categories 
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Table 1  Baseline of 
clinicopathological data of 
patients and the expression of 
TLR 5, 7, and 9 with relation to 
HPV and p16 status
HPV+ HPV- P p16+ p16− P Missing
Sex
 Male 81 (54.0) 69 (46.0) 89 (59.3) 61 (40.7)
 Female 24 (46.2) 28 (53.8) 0.329* 28 (53.8) 24 (46.2) 0.490* 0
Agea
 Lowest 1/3 37 (55.2) 30 (44.8) 41 (61.2) 26 (38.8)
 Middle 1/3 37 (54.4) 31 (45.6) 43 (63.2) 25 (36.8)
 Highest 1/3 31 (46.3) 36 (53.7) 0.301* 33 (49.3) 34 (50.7) 0.163* 0
Smoking
 Never 24 (92.3) 2 (7.7) 24 (92.3) 2 (7.7)
 Earlier 35 (71.4) 14 (28.6) 39 (79.6) 10 (20.4)
 Currently 26 (27.1) 70 (72.9) <0.001* 31 (32.3) 65 (67.7) <0.001* 32
Alcohol abuse
 Never 41 (67.2) 20 (32.8) 41 (67.2) 20 (32.8)
 Earlier 6 (25.0) 18 (75.0) 9 (37.5) 15 (62.5)
 Currently 9 (23.7) 29 (76.3) <0.001* 12 (31.6) 26 (68.4) <0.001* 72
T class
 T1 20 (52.6) 18 (47.4) 24 (63.2) 14 (36.8)
 T2 38 (50.0) 38 (50.0) 45 (59.2) 31 (40.8)
 T3 25 (54.3) 21 (45.7) 24 (57.2) 22 (47.8)
 T4 22 (52.4) 20 (47.6) 0.871* 24 (57.1) 18 (42.9) 0.461* 0
N class
 N0–N1 27 (40.9) 39 (59.1) 32 (48.5) 34 (51.5)
 N2–N3 78 (57.4) 53 (42.6) 0.029* 85 (62.5) 51 (37.5) 0.059* 0
Stage
 I–II 10 (33.3) 20 (66.7) 14 (46.7) 16 (53.3)
 III–IV 95 (55.2) 77 (44.8) 0.027* 103 (59.9) 69 (40.1) 0.177* 0
Tumor site
 Lateral wall 77 (65.8) 40 (34.2) 81 (69.2) 36 (30.8)
 Anterior wall 25 (41.0) 36 (59.0) 31 (50.8) 30 (49.2)
 Posterior wall 0 (0.0) 3 (100.0) 1 (33.3) 2 (66.7)
 Superior wall 3 (14.3) 18 (85.7) <0.001** 4 (19.0) 17 (81.0) <0.001** 0
Grade
 1 3 (16.7) 15 (83.3) 4 (22.2) 14 (77.8)
 2 32 (41.0) 46 (59.0) 39 (50.0) 39 (50.0)
 3 70 (66.0) 36 (34.0) <0.001* 74 (69.8) 32 (30.2) <0.001* 0
Treatment
 Sx ± (C)RT 72 (55.4) 58 (44.6) 76 (58.5) 54 (41.5)
 (C)RT ± Sx 33 (45.8) 39 (54.2) 0.193* 41 (56.9) 31 (43.1) 0.834* 0
TLR 5
 0 47 (79.7) 12 (20.3) 49 (83.1) 10 (16.9)
 1 27 (73.0) 10 (27.0) 32 (86.5) 5 (13.5)
 2 23 (30.3) 53 (69.7) 26 (34.2) 50 (65.8)
 3 8 (26.7) 22 (73.3) <0.001* 10 (33.3) 20 (66.7) <0.001* 0
TLR 7
 1 6 (12.8) 41 (87.2) 6 (12.8) 41 (87.2)
 2 44 (51.2) 42 (48.8) 49 (57.0) 37 (43.0)
 3 55 (79.7) 14 (20.3) <0.001* 62 (89.9) 7 (10.1) <0.001* 0
TLR 9
 0 7 (77.8) 2 (22.2) 6 (66.7) 3 (33.3)
 1 23 (76.7) 7 (23.3) 26 (86.7) 4 (13.3)
 2 53 (57.6) 39 (42.4) 57 (62.0) 35 (38.0)
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were as follows: 0 = 91.5%, 1 = 84.6%, 2 = 76.9%, and 
3 = 33.3%. Patients with high TLR 7 expression had better 
DSS. According to TLR 7 staining categories, the 5-year 
DSS of patients were as follows: 1 = 33.3%, 2 = 76.7%, and 
3 = 92.6%.
In the group of patients with a HPV-negative tumor, low 
TLR 5 expression was associated with poor 5-year distant 
RFS. For patients with HPV-negative tumors, the TLR 5, 7, 
and 9 expression did not associate with DSS.
TLR 5 and 7 presented as independent prognostic 
factors in HPV‑positive OPSCC (Table 4)
In multivariate analysis of all 202 patients, advanced 
regional metastasis (N2–N3) presented as an independent 
risk factor for poor DSS. For TLR 7 and T class, the overall 
P value remained non-significant, though differences were 
found between subgroups. TLR 7 interacted with HPV 
status (P = 0.027), indicating that the analysis should be 
stratified by HPV status. TLR 5 did not interact with HPV 
status (P = 0.202). Among HPV-positive OPSCC patients, 
high TLR 5 and low TLR 7 presented as independent fac-
tors worsening DSS. No other factors showed independent 
statistical significance for DSS. In HPV-negative OPSCC, 
TLR 5 and 7 were not independent factors for DSS. In this 
patient group, male gender and advanced regional metastasis 
(N2-3) were independent risk factors for poor DSS.
Multivariate analysis with p16 expression
In the whole study population (n = 202), the only inde-
pendent factor affecting the DSS was presence of regional 
advanced metastases (N2–3). Similarly, as in multivariate 
analysis with HPV status, statistically significant hazard 
ratios (HRs) were found in the subgroup analyses between T 
classes, TLR 5 expression, and TLR 7 expression, although 
the overall P value remained non-significant. Although, 
there was statistically significant interaction neither between 
p16 and TLR 5 (P = 0.053), nor between p16 and TLR 7 
(P = 0.244), we performed the multivariate analysis sepa-
rately on all patients and patients stratified by p16 status 
(Supplementary Table 1). In the p16-positive subgroup, high 
TLR 5 expression was a factor affecting poor DSS, but the 
association with TLR 7 and DSS remained absent.
Discussion
To our knowledge, this is the first study to suggest that high 
expression of TLR 5 and low expression of TLR 7 might 
be related to poor prognosis of HPV-related OPSCC. The 
Lateral wall tonsils and tonsillar pillars, Anterior wall base of tongue and vallecula, Superior wall soft pal-
ate and uvula
* Chi-square test, asymptotic P value
** Chi-square test, exact P value
a Age groups: lowest 1/3 ≤54.4 years. Middle 1/3 >54.4, <61.6 years. Highest 1/3 ≥61.1 years
Table 1  (continued) HPV+ HPV- P p16+ p16− P Missing
 3 22 (31.0) 49 (69.0) <0.001* 28 (39.4) 43 (60.6) <0.001** 0
Fig. 1  a HPV in  situ-positive OPSCC. b p16-positive OPSCC. c 
TLR 5-positive OPSCC. d TLR 7-positive OPSCC. e TLR 9-positive 
OPSCC. f HPV in  situ-negative OPSCC. g p16-negative OPSCC. h 
TLR 5-negative OPSCC. i TLR 7-negative OPSCC. j TLR 9-negative 
OPSCC. Scale bar length 100 μm. Magnification ×200
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background for this study is our recent finding showing 
differences in the expression patterns of TLR 5, 7, and 9 
according to tumor HPV status in OPSCC [16]. By includ-
ing a larger series of tumors in this study, we confirmed 
our previous findings. In addition, we demonstrated that the 
expression patterns of TLRs 5, 7, and 9 are significantly 
associated with several patient and disease characteristics, 
most of which are also known to be linked with HPV status. 
These include smoking, heavy drinking, T class, N class, 
stage, tumor grade, and site [1, 4, 5, 7, 29].
HPV-positive and HPV-negative tumors vary in response 
to treatment and have markedly different prognoses. In the 
latest WHO classification of Head and Neck Tumours, they 
are classified as distinct entities [30]. Our findings showing 
almost an opposite TLR expression between these tumors 
suggest that these tumors evoke distinct immunological 
reactions. The fact that HPV-positive tumors respond well 
to non-surgical treatment, may reflect their different immu-
nological nature. In our study, TLR 5 was more often less 
expressed and TLR 7 highly expressed in HPV-positive 
tumors. In addition, these staining patterns were noted 
among non-smokers and among patients who were not heavy 
drinkers. However, currently about half of the OPSCC recur-
rences develop among HPV-positive patients, along with the 
increasing relative rate of HPV-associated disease [8]. Our 
results may offer a potential prognostic biomarker in survival 
stratification for this growing patient group.
In various cancers, TLR 5 and 7 have been suggested 
to have either a prognostic role in in vivo studies [17–21, 
27], or a functional role in in vitro studies [31–36]. Kaup-
pila et al. suggested that high TLR 5 expression is asso-
ciated with high rate of mortality and recurrences in oral 
mobile tongue SCC [17], and Ni et al. suggested that high 
expression of TLR 7 could improve survival in oral SCC 
[21]. Although they did not study the HPV status in their 
series, HPV negativity in oral SCC is highly probable [37]. 
Therefore, our result showing that TLR 5 and 7 expression 
patterns are not associated with survival in HPV-negative 
OPSCC is in contrast with these findings. However, results 
for TLR 5 expression have been conflicting, as Mäkinen 
et al. suggested that low TLR 5 expression in oral mobile 
tongue SCC predicted poor prognosis [27].
Activation of TLR 5 has been shown to cause tumor pro-
gression in gastric cancer [32] and salivary gland adenocar-
cinoma [31], but in oral SCC, there is no association between 
TLR 5 activation and tumor progression [38]. According to a 
study by Burdelya et al. [39], TLR 5 activation had radiopro-
tective effect. Tissues being protected from radiation stress, 
however, were located adjacent to a tumor, and no decrease 
in the radiosensitivity of the tumor was observed. According 
to our results we can speculate that HPV-positive tumors, 
which are normally radiosensitive, might lose their reactiv-
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Fig. 2  Disease-specific survival 
curves according to expression 
of TLR 5 and 7 in OPSCC, 
also separately in HPV-positive 
and HPV-negative OPSCC. a 
TLR 5 expression in OPSCC. 
Low staining is associated with 
good DSS. b TLR 7 expression 
in OPSCC. High expression 
predicts good prognosis. c TLR 
5 expression in HPV-positive 
OPSCC. Low expression of 
TLR is associated with good 
outcome, whereas high expres-
sion relates to impaired DSS. d 
TLR 5 expression in HPV-
negative OPSCC. No impact 
on survival was found. e TLR 
7 expression in HPV-positive 
OPSCC. High expression is 
associated with excellent sur-
vival rate, whereas low expres-
sion relates to impaired DSS. 
f TLR 7 expression in HPV-
negative OPSCC. No impact on 
survival was found
Table 3  TLR 5, 7, and 9 expression and 5-year locoregional and distant RFS
Log-rank test was used in the statistical analysis. Death with disease and death with no evidence of disease were censored
TLR 5 TLR 7 TLR 9
0 (%) 1 (%) 2 (%) 3 (%) P 1 (%) 2 (%) 3 (%) P 0 (%) 1 (%) 2 (%) 3 (%) P
All tumors n = 202
 Locoregional RFS 95.3 93.8 76.9 73.1 0.004 75.2 85.6 90.8 0.062 88.9 96.3 89.5 74.5 0.057
 Distant RFS 89.6 93.9 93.2 100.0 0.390 88.1 93.4 95.5 0.490 100.0 92.9 92.0 93.6 0.867
HPV+ tumors n = 105
 Locoregional RFS 97.8 96.2 90.0 53.6 <0.001 60.0 92.4 96.2 0.003 100.0 100.0 93.7 80.4 0.072
 Distant RFS 93.4 92.1 94.7 100.0 0.910 60.0 92.4 98.1 <0.001 100 95.5 91.7 94.4 0.816
HPV− tumors n = 97
 Locoregional RFS 85.7 85.7 70.7 80.7 0.503 77.6 76.7 68.6 0.669 50.0 80.0 81.9 71.7 0.608
 Distant RFS 75.0 100.0 92.3 100.0 0.030 92.5 95.1 85.7 0.504 100.0 83.3 92.2 93.4 0.792
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Stimulation of TLR 7 promotes cancer-cell survival and 
chemoresistance in adenocarcinoma and SCC of the lung 
[33, 34]. In oral cancer, however, activation of TLR 7 with 
imiquimod, a pharmaceutical product used clinically for 
basal cell carcinoma, reduces tumor growth [35] and in 
breast cancer enhances radiosensitivity [36]. We may only 
speculate if radiosensitivity of HPV-positive tumors could 
be associated with TLR 7 overexpression in HPV-positive 
OPSCC. This research thus raises the question of whether 
including TLR 5 signaling downregulation and TLR 7 sign-
aling upregulation would benefit OPSCC treatment.
HPV has previously been shown to down-regulate TLR 
9 in cervical cancer [40]. In addition, TLR 9 is shown to be 
down-regulated by other oncogenic viruses [41–44]. Like-
wise, in our series, TLR 9 was low in HPV-positive OPSCC, 
even though the role of TLR 9 does not seem to be as impor-
tant as that of TLR 5 and 7.
In our study, the retrospective nature of the data, and 
non-randomization of patients can predispose the results 
for unknown bias. The available details were limited espe-
cially regarding history of smoking and alcohol abuse. 
However, we also tested multivariate analysis with smok-
ing details, but no change in the significance was observed. 
The 95% CI of TLR 5 and 7 HR in multivariate analysis 
of HPV-positive subgroups were broad, which is prob-
ably explained by the low number of events and patients 
presenting adverse TLR expression in the HPV-positive 
group. This may explain why multivariate analysis strati-
fied by p16 failed to show association between DSS and 
TLR 7. Consequently, as the sample size remained limited, 
we must avoid robust conclusions concerning survival 
results. In two cases, specimens were unavailable before 
CRT, and the treatment effect on TLR expression cannot 
be excluded, but statistical analysis without these patients 
did not affect the results.
In conclusion, according to our results, the expression of 
TLR 5, 7, and 9 in OPSCC is associated with HPV status in 
the tumor tissue. Our results suggest that high TLR 5 and 
Table 4  Univariate and multivariate Cox regression analysis for DSS in a series of 202 OPSCC patients and separately for  those with either 
a HPV-positive tumor or a HPV-negative tumor
Univariate analysis Multivariate analysis Multivariate analysis Multivariate analysis
All patients All patients HPV-positive patients HPV-negative patients
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Sex
Male vs. female 2.2 1.0–4.9 0.054 2.2 1.0–5.0 0.061 1.1 0.3–4.2 0.874 3.4 1.1–10.4 0.029
Smoking 0.038
Earlier vs. never 1.7 0.5–6.0 0.439
Currently vs. never 3.3 1.0–10.7 0.048
T class 0.060 0.063 0.235 0.266
 T2 vs. T1 3.0 0.7–5.3 0.178 2.0 0.7–5.8 0.174 2.3 0.2–21.9 0.463 2.3 0.7–7.6 0.188
 T3 vs. T1 1.8 0.6–5.3 0.284 1.2 0.4–3.6 0.747 2.2 0.2–22.9 0.511 1.0 0.3–3.8 0.980
 T4 vs. T1 3.6 1.3–10.0 0.013 3.1 1.1–8.9 0.031 5.5 0.6–48.5 0.122 2.4 0.7–8.4 0.169
N class
 N2–3 vs. N0–1 2.1 1.0–4.2 0.037 3.6 1.7–7.5 0.001 4.0 0.8–19.2 0.084 3.4 1.4–8.2 0.007
TLR 5 0.005 0.228 0.033 0.761
 1 vs. 0 1.9 0.7–5.5 0.218 2.0 0.7–5.7 0.169 3.6 0.7–19.3 0.129 2.1 0.4–9.5 0.353
 2 vs. 0 2.6 1.1–6.3 0.027 1.7 0.7–4.2 0.280 2.4 0.6–10.2 0.240 1.4 0.4–5.2 0.594
 3 vs. 0 4.9 2.0–12.2 0.001 2.8 1.0–7.8 0.051 11.7 2.1–63.6 0.005 1.8 0.4–7.8 0.405
TLR 7 0.002 0.085 0.001 0.739
 1 vs. 3 4.4 1.9–10.0 <0.001 3.2 1.1–9.0 0.027 20.8 4.0–107.1 <0.001 1.6 0.4–6.0 0.471
 2 vs. 3 2.4 1.1–5.5 0.031 2.1 0.9–5.2 0.089 2.4 0.7–8.2 0.158 1.3 0.4–4.5 0.693
TLR 9 0.584
 0 vs. 3 0.0 – 0.975
 1 vs. 3 0.5 0.2–1.3 0.165
 2 vs. 3 0.8 0.5–1.5 0.567
HPV
 HPV− vs. HPV+ 2.2 1.2–4.0 0.007 1.6 0.8–3.3 0.181
Treatment
 (C)RT ± Sx vs. Sx ± (C)RT 1.0 0.6–1.8 0.975
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low TLR 7 expression might be related to poor outcome 
among HPV-positive OPSCC.
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